Add like
Add dislike
Add to saved papers

Meprin-alpha metalloproteases enhance lipopolysaccharide-stimulated production of tumour necrosis factor-alpha and interleukin-1beta in peripheral blood mononuclear cells via activation of NF-kappaB.

Regulatory Peptides 2010 Februrary 26
Lipopolysaccharide (LPS) induces the expression of a wide range of pro-inflammatory mediators via NF-kappaB activation. These pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), may be important in triggering atherogenesis. We have previously observed that actinonin, a meprin inhibitor, suppressed the formation of atherosclerotic plaques and, in in vitro experiments, actinonin also had an effect on the way LPS altered THP-1 cell function. The aim of the present study was to investigate whether meprin-alpha regulates LPS-induced production of TNF-alpha and IL-1beta in peripheral blood mononuclear cells (PBMCs) and its potential mechanisms of action. We observed that meprin-alpha could enhance LPS-induced expression of TNF-alpha and IL-1beta mRNA and protein in a time- and concentration-dependent manner, assessed using real-time PCR and ELISA. Meprin-alpha also significantly increased LPS-induced NF-kappaB transcriptional activity. Furthermore, we assessed the effects of meprin-alpha specific siRNA on the production of TNF-alpha and IL-1beta to examine whether meprin-alpha was involved in the process of LPS-induced activation of PBMCs. Our results show that LPS-induced IL-1beta and TNF-alpha production by PBMCs was significantly reversed by meprin-alpha specific siRNA. In addition, the augmentation of meprin-alpha of the LPS-induced expression of TNF-alpha and IL-1beta was significantly decreased by Bay-117082, an inhibitor of NF-kappaB. In conclusion, our data indicate that meprin-alpha is capable of increasing LPS-induced production of cytokines in peripheral blood mononuclear cells, which might be associated with the activation of NF-kappaB.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app